Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Abstract Background To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of...

Bibliografiset tiedot
Päätekijät:	Maximilian Günther, Leopold Hentschel, Markus Schuler, Theresa Müller, Katharina Schütte, Yon-Dschun Ko, Ingo Schmidt-Wolf, Ulrich Jaehde
Aineistotyyppi:	Artikkeli
Kieli:	English
Julkaistu:	BMC 2023-07-01
Sarja:	BMC Cancer
Aiheet:	Patient-reported outcomes PRO-CTCAE Breast cancer Symptom burden Multiple myeloma Prostate cancer
Linkit:	https://doi.org/10.1186/s12885-023-11115-7

Samankaltaisia teoksia

A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
Tekijä: Mille Guldager Christiansen, et al.
Julkaistu: (2023-07-01)

Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Tekijä: Minji K. Lee, et al.
Julkaistu: (2020-12-01)

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
Tekijä: Christina Baeksted, et al.
Julkaistu: (2017-09-01)

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tekijä: Tian Qi Wang, et al.
Julkaistu: (2018-10-01)

Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
Tekijä: Evalien Veldhuijzen, et al.
Julkaistu: (2020-10-01)

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE® to Provide Two Distinct and Complementary Perspectives
Tekijä: Minasian LM, et al.
Julkaistu: (2022-12-01)

Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Tekijä: Kristin M. Schroeder, et al.
Julkaistu: (2023-06-01)

Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tekijä: Tempei Miyaji, et al.
Julkaistu: (2017-12-01)

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer
Tekijä: Thomas Jordan, et al.
Julkaistu: (2024-04-01)

Score equivalence of paper-, tablet-, and interactive voice response system-based versions of PROMIS, PRO-CTCAE, and numerical rating scales among cancer patients
Tekijä: Minji K. Lee, et al.
Julkaistu: (2021-09-01)

Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
Tekijä: Caterina Caminiti, et al.
Julkaistu: (2024-10-01)

Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial
Tekijä: Lisa M. Wintner, et al.
Julkaistu: (2020-10-01)

Patient-reported outcomes for patients with breast cancer undergoing radiotherapy: A single-center registry experience
Tekijä: Brady S. Laughlin, et al.
Julkaistu: (2022-08-01)

Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials
Tekijä: Nilesh Ranjan, et al.
Julkaistu: (2022-05-01)

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
Tekijä: Yanyan Zhu, et al.
Julkaistu: (2023-03-01)

Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Tekijä: Lærke K. Tolstrup, et al.
Julkaistu: (2019-03-01)

Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag
Tekijä: Stacy Davis, et al.
Julkaistu: (2023-12-01)

Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients
Tekijä: Marieke van Son, M.D., et al.
Julkaistu: (2021-03-01)

Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary
Tekijä: Faith A.P. Zeng, et al.
Julkaistu: (2022-12-01)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
Tekijä: Márcio A. Diniz, et al.
Julkaistu: (2021-11-01)

Effect of acupuncture in prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: study protocol for a randomized controlled trial
Tekijä: Qi-wei Li, et al.
Julkaistu: (2017-04-01)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
Tekijä: Agnese Barnabei, et al.
Julkaistu: (2022-03-01)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Tekijä: Shah, V, et al.
Julkaistu: (2020)

Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer
Tekijä: Roman O. Kowalchuk, et al.
Julkaistu: (2021-11-01)

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022
Tekijä: Marwan A. Alrasheed, et al.
Julkaistu: (2024-06-01)

Myeloma and Cystoisospora belli
Tekijä: Pathum Sookaromdee, et al.
Julkaistu: (2021-08-01)

A Case Report of Multiple Myeloma Concurrent with Gastric Adenocarcinoma
Tekijä: Marziyeh Ghalamkari, et al.
Julkaistu: (2022-07-01)

Case Report: Pulmonary Kaposi Sarcoma in a non-HIV patient [version 1; referees: 2 approved]
Tekijä: Arber Kodra, et al.
Julkaistu: (2015-10-01)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved]
Tekijä: Albane Joly-Battaglini, et al.
Julkaistu: (2016-01-01)

Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity
Tekijä: Imke Ortland, et al.
Julkaistu: (2022-08-01)

Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents
Tekijä: Yuko Shirouchi, et al.
Julkaistu: (2024-08-01)

Clinical profile of patients with cardiac amyloidosis in India
Tekijä: Bishav Mohan, et al.
Julkaistu: (2023-01-01)

Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy
Tekijä: Seungwoo Cha, et al.
Julkaistu: (2018-12-01)

Gallbladder Metastases: A Report of Two Cases
Tekijä: Mohamad Mouchli, et al.
Julkaistu: (2019-03-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
Tekijä: Diego Acosta-Alvear, et al.
Julkaistu: (2015-09-01)

CYTOKINE REGULATION IN THE COURSE OF MULTIPLE MYELOMA PROGRESSION
Tekijä: O. V. Smirnova, et al.
Julkaistu: (2015-06-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
Tekijä: Aiken Dao, et al.
Julkaistu: (2022-12-01)

Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial
Tekijä: Michael J. Hassett, et al.
Julkaistu: (2022-06-01)

Using a multi-omics approach to identify novel targets in multiple myeloma
Tekijä: James-Bott, A
Julkaistu: (2022)

A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways
Tekijä: Parinya Samart, et al.
Julkaistu: (2022-07-01)